Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

BACKGROUND: Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of trial results in the real world are limited...

全面介紹

Na minha lista:
書目詳細資料
發表在:Open Forum Infect Dis
Main Authors: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Van Anglen, Lucinda J, Schroeder, Claudia P, Dillon, Ryan J, Marcella, Stephen W, Garey, Kevin W
格式: Artigo
語言:Inglês
出版: Oxford University Press 2020
主題:
Major Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186524/
https://ncbi.nlm.nih.gov/pubmed/32363211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa097
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍